Boehringer Ingelheim to expand its AI footprint in UK, in £150M investmentnews2026-04-20T14:45:13+00:00April 20th, 2026|Endpoints News|
New CDC pick Schwartz is praised by public health prosnews2026-04-17T17:17:43+00:00April 17th, 2026|Endpoints News|
Biovac gets $108M backing for vaccine factory in South Africanews2026-04-17T13:32:30+00:00April 17th, 2026|Endpoints News|
Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggestsnews2026-04-17T11:15:32+00:00April 17th, 2026|Endpoints News|
Lilly’s obesity pill heads for diabetes filing after heart risk trialnews2026-04-16T11:26:00+00:00April 16th, 2026|Endpoints News|
Updated: FDA will reclassify at least a dozen peptides, teeing up potential telehealth winnews2026-04-15T19:12:44+00:00April 15th, 2026|Endpoints News|
Replimune looks ahead as repeat CRL speeds the company’s declinenews2026-04-14T17:19:37+00:00April 14th, 2026|Endpoints News|
J&J increasingly confident it can manage Stelara cliff, but work remainsnews2026-04-14T14:47:25+00:00April 14th, 2026|Endpoints News|
FDA approves Travere’s Filspari as first drug for the kidney disease FSGSnews2026-04-14T09:02:09+00:00April 14th, 2026|Endpoints News|
White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says news2026-04-13T18:52:23+00:00April 13th, 2026|Endpoints News|
